Chicago Capital LLC Has $18.17 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Chicago Capital LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 1,390.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 203,476 shares of the medical equipment provider’s stock after purchasing an additional 189,824 shares during the quarter. Chicago Capital LLC’s holdings in Boston Scientific were worth $18,174,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Quarry LP bought a new position in shares of Boston Scientific during the second quarter worth about $33,000. Czech National Bank raised its position in shares of Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock worth $25,139,000 after acquiring an additional 19,833 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Boston Scientific by 39.9% during the third quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock worth $1,461,000 after acquiring an additional 4,972 shares during the last quarter. Miracle Mile Advisors LLC raised its position in shares of Boston Scientific by 4.0% during the third quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock worth $440,000 after acquiring an additional 203 shares during the last quarter. Finally, Bank of New Hampshire raised its position in shares of Boston Scientific by 52.6% during the third quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after acquiring an additional 770 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Boston Scientific stock opened at $102.40 on Monday. Boston Scientific Co. has a 52 week low of $62.63 and a 52 week high of $104.25. The business has a 50-day simple moving average of $93.47 and a 200 day simple moving average of $86.27. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a market cap of $150.92 billion, a price-to-earnings ratio of 84.63, a PEG ratio of 2.68 and a beta of 0.80.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Sanford C. Bernstein raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Raymond James lifted their target price on Boston Scientific from $101.00 to $119.00 and gave the stock a “strong-buy” rating in a report on Friday. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Citigroup lifted their target price on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average target price of $99.73.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.